Interní Med. 2001; 3(9): 401-406

Léčba hyperlipidémií v primární a sekundární prevenci ischemické choroby srdeční

MUDr. Richard Češka CSc
III. interní klinika VFN a 1. LF UK, Praha

Keywords: hyperlipoproteinaemia, statins, fibrats, primary and secundary prevention of ischemic heart disease.

Published: December 31, 2001  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Češka R. Léčba hyperlipidémií v primární a sekundární prevenci ischemické choroby srdeční. Interní Med. 2001;3(9):401-406.

Pokles kardiovaskulární morbidity a mortality v ČR lze jistě alespoň z části vysvětlit zlepšením péče o nemocné s hyperlipoproteinémiemi. V současné době vstupují v platnost nová pravidla pro předepisování statinů, ze kterých lovastatin a simvastatin mohou předepisovat v sekundární prevenci ischemické choroby srdeční (ICHS) i praktičtí lékaři. Předložený článek se snaží ukázat základní principy diagnostiky a léčby hyperlipoproteinémií pro lékaře v praxi. Jsou diskutována moderní doporučení evropská, americká i domácí.

Patient with Hyperlipidaemia in the Primary and Secundary Prevention of Ischaemic Hearth Disease

Decreasing of cardiovaskular morbidity and mortality in the Czech Republic is possible explain nearly partly by bettering of care in patients with hyperlipoproteinaemia. This time new rules for statins administration are valid, where lovastatin and simvastatin could in the secundary care against ischaemic heart disease administrate a generalle practicionar too. The presented article will tray to show the basic principles of diagnostics and treatment of hyperlipoproteinaemia to the physicians providing practice. The modern recomanding from Europe, Americam and Czech are discused.

Download citation

References

  1. McIntosh, H. D.: Risk factors for cardiovascular disease and death: A clinical perspective, JACC, 14, 1989, 24-30. Go to original source... Go to PubMed...
  2. Češka, R.:Cholesterol a ateroskleróza: Léčba hyperlipidémií, Maxdorf, Praha, 1999.
  3. Wood, D. et al. on behalf of the Task Force. Prevence of coronary heart disease in clinical practice. Recommendations of the second joint task force of European and other societies on coronary prevention, Eur. Heart j. 19, 1998, 1434-1503. Go to original source... Go to PubMed...
  4. Executive summary of the third report of the NCEP expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult treatment panel III), JAMA, 285, 2001, 2486-2497. Go to PubMed...
  5. Češka, R. et al.: Doporučení pro léčbu hyperlipoproteinémií v dospělosti, vypracovaná výborem České společnosti pro aterosklerózu Čas. Lék. čes. 136, 1997, 257-261.
  6. Cífková, R. za členy společné pracovní skupiny: Prevence ischemické choroby srdeční v dospělém věku, Kapitoly z kardiologie, 2, 2000, 122-139.
  7. EAS: Prevention of coronary heart disease: Scientific background and new clinical guidelines, Nutr. Metab. Cardiovasc. Dis., 2, 1992, 113-156.
  8. Scandinavian Simvastatin Survival Study Group:Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease The Scandinavian Survival Study (4S), Lancet, 1994, 344, 1383-1389. Go to original source...
  9. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med., 1998, 339, 1349-1357. Go to original source... Go to PubMed...
  10. Rubins, H. B., Robins, S. J., Collins, D. et al. for the Veteran Afairs HighDensity Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol, N. Engl. J. Med., 1999, 341, 410-418. Go to original source... Go to PubMed...
  11. Shepherd, J., Cobbe, S. M., Ford, I. et al.: Prevention of coronary heart diseasewithz pravastatin in men with hypercholesterolemia, N. Engl. J. Med, 1995, 333, 1301-1307. Go to original source... Go to PubMed...
  12. Downs, J. R., Clearfield, M., Weis, S. et al. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels, JAMA, 1998, 279, 1615-1622. Go to original source... Go to PubMed...
  13. Haffner, S. M.: Coronary heart disease in patients with diabetes, N. Engl. J. Med., 342, 2000, 1040-1042. Go to original source... Go to PubMed...
  14. ADA: Management of dyslipidemia in adults with diabetes, Diabetes Care, 24, Suppl. 1, 2001, S58-S61.




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.